(Q84774654)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

K A Smith

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Z Qiu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

V L Tam

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

B L Tam

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

D K Joea

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Quach

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

X Liu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

M Pold

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

U M Malyankar

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Bot

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

20 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

63-76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/cgt.2010.45

10 February 2020

exact match

0 references

cites work

Where are we with adjuvant therapy of stage III and IV melanoma in 2009?

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Molecular-targeted therapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Tumor-specific shared antigenic peptides recognized by human T cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

The use of melanosomal proteins in the immunotherapy of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Extraction and Use of Melanoma-Associated Protein for Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Adoptive cell therapy for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Cancer vaccines: a promising cancer therapy against all odds

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Intralymphatic immunization enhances DNA vaccination.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

DNA vaccines against human immunodeficiency virus type 1 in the past decade

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

DNA vaccines: precision tools for activating effective immunity against cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Toll-like receptors on tumor cells facilitate evasion of immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated PD-1 expression

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.45

7 January 2021

Identifiers

DOI

10.1038/CGT.2010.45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20725097%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference